In both the United States and other parts of the world, kidney stones are becoming an increasingly regular occurrence. There is a correlation between type 2 diabetes and an increased risk of kidney stones; however, there are a variety of treatment options available for this condition that have the ability to minimize the risk of kidney stones formation.
The use of sodium-glucose contratransporter 2 (SGLT2) inhibitors was found to be connected with a reduced risk of developing kidney stones, according to the findings of researchers at Mass General Brigham. Their results were later reported in the journal JAMA Internal Medicine.
The investigation was carried out by researchers from Massachusetts General Hospital and Brigham and Women’s Hospital working together to undertake the investigation. The research incorporated information obtained from three national databases pertaining to individuals diagnosed with type 2 diabetes who were seen in the course of their regular clinical practice. In their study, the researchers looked at information from 716,406 people who had type 2 diabetes and had started taking either an SGLT2 inhibitor or one of two additional types of diabetes medications known as GLP1 receptor agonists or dipeptidyl peptidase 4 (DPP4) inhibitors.
In comparison to patients who were using GLP1 agonists, those who started taking SGLT2 inhibitors had a thirty percent lower risk of developing kidney stones, and those who started taking DPP4 inhibitors had a twenty-five percent lower risk altogether. The findings were constant regardless of factors such as gender, race or ethnicity, a previous history of chronic renal illness, or obesity.
“Our findings could help inform clinical decision making for patients with diabetes who are at risk of developing kidney stones,” said corresponding author Julie Paik, MD, ScD, MPH, of Brigham and Women’s Hospital’s Divisions of Pharmacoepidemiology and Pharmacoeconomics and Renal (Kidney) Medicine.
For more information: Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes, JAMA Internal Medicine (2024). DOI: 10.1001/jamainternmed.2023.7660
more recommended stories
Citrus and Grape Compounds Help Prevent Type 2 DiabetesA new clinical trial highlights the.
Personalized Pain Care Transforms Parkinson’s TreatmentNew UniSA research underscores the urgent.
Genetic Diversity Explains Obesity Risk DifferencesCross-ancestry Study Identifies Novel Obesity Genes.
Meniscal Tear and OA Pain Improved by Home ExerciseHome Exercise Proves Effective for Knee.
AI ECG Model Outperforms Standard STEMI TriageNovel AI ECG Model Outperforms Standard.
New Software Transforms Real-Time Pathogen SurveillanceReal-Time Pathogen Surveillance Software Transforms Environmental.
Bright Nights May Increase Stroke, Heart Failures in AdultsBright Nights are tied to increased.
Cannabis Use Linked to Regular Tobacco in US YouthCannabis Use and Tobacco Risk: A.
Mediterranean Diet Reduces Endometriosis Risk in WomenMediterranean Diet and Endometriosis: A Promising.
Night Shifts May Trigger Irritable Bowel Syndrome (IBS)Night Shifts and Digestive Health: Linking.
Leave a Comment